Levodopa/carbidopa/entacapone (Stalevo)HAUSER, Robert A.Neurology. 2004, Vol 62, Num 1, pp S64-S71, issn 0028-3878, SUP1Article

PRECLINICAL TOXICOLOGICAL STUDIES OF CARBIDOPA AND COMBINATIONS OF CARBIDOPA AND LEVODOPA = ETUDES TOXICOLOGIQUES PRECLINIQUES DU CARBIDOPA ET DE L'ASSOCIATION DU CARBIDOPA ET DU LEVODOPAZWICKEY RE; PECK HM; BAGDON WJ et al.1974; TOXICOL. APPL. PHARMACOL.; U.S.A.; DA. 1974; VOL. 29; NO 2; PP. 181-195; BIBL. 1P. 1/2Article

Carbidopa/Levodopa Pharmacy Errors in Parkinson's DiseaseKHADEM, Nasim R; NIRENBERG, Melissa J.Movement disorders. 2010, Vol 25, Num 16, pp 2867-2871, issn 0885-3185, 5 p.Article

L'ALPHA-METHYLDOPA HYDRAZINE (CARBIDOPA) COMBINED WITH L-DOPA IN THE TREATMENT OF PARKINSON'S DISEASE = L'HYDRAZINE DE LA L-ALPHA -METHYLDOPA (CARBIDOPA) ASSOCIEE A LA L-DOPA DANS LE TRAITEMENT DE LA MALADIE DE PARKINSONGLASGOW GL; HENLEY JW; WILLOUGHBY EW et al.1974; AUSTRAL. NEW ZEAL. J. MED.; AUSTRAL.; DA. 1974; VOL. 4; NO 4; PP. 373-378; BIBL. 24REF.Article

THERAPY OF INTENTION MYOCLONUS WITH L-5-HYDROXYTRYPTOPHAN AND A PERIPHERAL DECARBOXYLASE INHIBITOR, MK486 = TRAITEMENT DU MYOCLONUS INTENTIONNEL PAR LE L-5 HYDROXYTRYPTOPHANE ET UN INHIBITEUR DE LA DECARBOXYLASE PERIPHERIQUE, LE MK486VAN WOERT MH; SETHY VH.1975; NEUROLOGY; U.S.A.; DA. 1975; VOL. 25; NO 2; PP. 135-140; BIBL. 35REF.Article

Quality of Life in Early Parkinson's Disease Treated with Levodopa/Carbidopa/EntacaponeFUNG, Victor S. C; HERAWATI, Lilie; YING WAN et al.Movement disorders. 2009, Vol 24, Num 1, pp 25-31, issn 0885-3185, 7 p.Article

Tyrosiro Hydroxylase Deficiency Presenting with a Biphasic Clinical CourseGIOVANNLELLO, T; LEUZZI, V; CARDUCCI, C et al.CARDUCCI, C et al.Neuropediatrics. 2007, Vol 38, Num 4, pp 213-215, issn 0174-304X, 3 p.Article

Are High Doses of Carbidopa a Concern? A Randomized, Clinical Trial in Parkinson's DiseaseBROD, Lissa S; ALDRED, Jason L; NUTT, John G et al.Movement disorders. 2012, Vol 27, Num 6, pp 750-753, issn 0885-3185, 4 p.Article

Oxidation of carbidopa by tyrosinase and its effect on murine melanomaGASOWSKA-BAJGER, Beata; FRACKOWIAK-WOJTASEK, Bozena; KOJ, Sabina et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 13, pp 3507-3510, issn 0960-894X, 4 p.Article

Evolution of the Bioavailability and other Pharmacokinetic Parameters of Levodopa (with Carbidopa) in RabbitsFERNDNDEZ, N; PRIETO, C; SIERRA, M et al.Methods and findings in experimental and clinical pharmacology. 2008, Vol 30, Num 6, pp 451-457, issn 0379-0355, 7 p.Article

Simultaneous kinetic determination of levodopa and carbidopa by H-point standard addition methodSAFAVI, Afsaneh; TOHIDI, Maryam.Journal of pharmaceutical and biomedical analysis. 2007, Vol 44, Num 1, pp 313-318, issn 0731-7085, 6 p.Article

STUDIES ON DL-5-HYDROXYTRYPTOPHAN-INDUCED HYPERACTIVITY IN MICE = ETUDES SUR L'HYPERACTIVITE INDUITE PAR LE DL-5-HYDROXYTRYPTOPHANE CHEZ LES SOURISMODIGH K.1974; ADV. BIOCHEM. PSYCHOPHARMACOL.; U.S.A.; DA. 1974; VOL. 10; PP. 213-217; BIBL. 10REF.Article

Carbidopa dosage modifies L-DOPA induced side effects and blood levels of L-DOPA and other aminoacids in advanced parkinsonismPAREJA, F. B; MARTINEZ-MARTIN, P; MURADAS, V et al.Acta neurologica scandinavica. 1985, Vol 72, Num 5, pp 506-511, issn 0001-6314Article

Use of integral and differential methods for the determination of L-dopa in pure form and pharmaceutical preparationsHELALEH, M. I. H; RAHMAN, N; JAMHOUR, R. M. A. Q et al.Journal of pharmaceutical and biomedical analysis. 1997, Vol 16, Num 2, pp 269-274, issn 0731-7085Article

Carbidopa/levodopa-responsive myoclonusFITZGERALD, David B; DRAGO, Valeria; SUTHERLAND, Dean et al.Movement disorders. 2007, Vol 22, Num 3, pp 392-395, issn 0885-3185, 4 p.Article

Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patientsEARLEY, C. J; ALLEN, R. P.Sleep (New York, NY). 1996, Vol 19, Num 10, pp 801-810, issn 0161-8105Article

Development and Application of a High-Performance Liquid Chromatographic Method for the Determination of In Vitro Drug Release of Levodopa, Carbidopa, and Entacapone from a Tablet FormulationDOSHI, Ashish S; UPADHYAY, Kalpesh J; MEHTA, Tushar N et al.Journal of AOAC International. 2009, Vol 92, Num 2, pp 394-403, issn 1060-3271, 10 p.Article

Response of Motor Complications in Cockayne Syndrome to Carbidopa-LevodopaNEILAN, Edward G; DELGADO, Mauricio R; DONOVAN, Melissa A et al.Archives of neurology (Chicago). 2008, Vol 65, Num 8, pp 1117-1121, issn 0003-9942, 5 p.Article

Entacapone in restless legs syndromeSHARIF, Ashfaq A.Movement disorders. 2002, Vol 17, Num 2, issn 0885-3185, p. 421Article

Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatmentBROWN, W. D; OAKES, T. R; DEJESUS, O. T et al.The Journal of nuclear medicine (1978). 1998, Vol 39, Num 11, pp 1884-1891, issn 0161-5505Article

Initiating Levodopa/Carbidopa Therapy With and Without Entacapone in Early Parkinson Disease: The STRIDE-PD StudySTOCCHI, Fabrizio; RASCOL, Olivier; KIEBURTZ, Karl et al.Annals of neurology. 2010, Vol 68, Num 1, pp 18-27, issn 0364-5134, 10 p.Article

Blood-brain barrier and neuronal membrane transport of 6-[¹⁸F]fluoro-L-DOPAYEE, Randa E; CHENG, David W; HUANG, Sung-Cheng et al.Biochemical pharmacology. 2001, Vol 62, Num 10, pp 1409-1415, issn 0006-2952Article

EFFECT OF CARBIDOPA ON THE METABOLISM OF L-DOPA IN THE PIGTAIL MONKEYBRONAUGH RL; WENGER GR; GARVER DL et al.1976; BIOCHEM. PHARMACOL.; G.B.; DA. 1976; VOL. 25; NO 14; PP. 1679-1681; BIBL. 19 REF.Article

Metabolism of carbidopa to alpha-methyldopamine and alpha-methylnorepinephrine in ratsSHELTON, R. C; FAROUK KAROUM; LIN-WHEI CHUANG et al.Biochemical pharmacology. 1985, Vol 34, Num 20, pp 3623-3626, issn 0006-2952Article

Design and optimization of a chemometrics-assisted spectrophotometric method for the simultaneous determination of levodopa and carbidopa in pharmaceutical productsDAMIANI, Patricia C; MOSCHETTI, Andrea C; ROVETTO, Adrian J et al.Analytica chimica acta. 2005, Vol 543, Num 1-2, pp 192-198, issn 0003-2670, 7 p.Article